SK bioscience Co.,Ltd. (KRX:302440)
South Korea flag South Korea · Delayed Price · Currency is KRW
54,000
-400 (-0.74%)
At close: Dec 5, 2025

SK bioscience Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
159,520312,702127,026225,28798,028
Short-Term Investments
408,147233,542275,3005,300-0
Trading Asset Securities
439,154611,864871,8161,250,2181,547,635
Cash & Short-Term Investments
1,006,8211,158,1081,274,1411,480,8061,645,663
Cash Growth
-24.86%-9.11%-13.96%-10.02%-
Accounts Receivable
113,72394,46212,92839,58538,006
Other Receivables
14,91993,9349,41450,07610,129
Receivables
128,641188,39622,34289,66148,135
Inventory
221,989211,12680,649187,406135,046
Prepaid Expenses
7,0755,7481,6131,6491,407
Other Current Assets
10,31913,2954,22424,1737,554
Total Current Assets
1,374,8451,576,6731,382,9691,783,6941,837,804
Property, Plant & Equipment
1,110,758982,607315,923293,057220,983
Long-Term Investments
72,59422,35742,7291,50021,610
Goodwill
53,90257,436---
Other Intangible Assets
73,41956,08414,1786,2993,973
Long-Term Deferred Tax Assets
168,150108,13559,21921,37010,242
Long-Term Deferred Charges
47,88211,0278,28111,88213,088
Other Long-Term Assets
21,22929,27729,14024,1292,422
Total Assets
2,922,7792,843,5961,852,4392,141,9312,110,123
Accounts Payable
35,27017,8183,37011,05363,812
Accrued Expenses
44,93854,29819,71630,24226,322
Short-Term Debt
---45,55011,671
Current Portion of Long-Term Debt
---38,00847,978
Current Portion of Leases
3,4126,9578,13712,2352,309
Current Income Taxes Payable
365.446,994-20,216101,486
Other Current Liabilities
238,006224,523104,397222,733206,374
Total Current Liabilities
321,992310,589135,620380,037459,952
Long-Term Debt
406,452383,331--35,503
Long-Term Leases
1,2662,52612,43617,5438,775
Pension & Post-Retirement Benefits
----4,246
Long-Term Deferred Tax Liabilities
74,22071,960---
Other Long-Term Liabilities
44,03352,737527.842,649335.24
Total Liabilities
847,964821,144148,584400,229508,811
Common Stock
39,18539,17438,41438,39238,250
Additional Paid-In Capital
1,235,6001,235,3761,160,4561,160,0081,157,064
Retained Earnings
500,295499,757549,421533,378405,305
Comprehensive Income & Other
58,65528,258-44,4359,924692.92
Total Common Equity
1,833,7351,802,5651,703,8551,741,7021,601,312
Minority Interest
241,080219,887---
Shareholders' Equity
2,074,8152,022,4521,703,8551,741,7021,601,312
Total Liabilities & Equity
2,922,7792,843,5961,852,4392,141,9312,110,123
Total Debt
411,131392,81420,574113,336106,236
Net Cash (Debt)
595,690765,2941,253,5681,367,4691,539,428
Net Cash Growth
-47.51%-38.95%-8.33%-11.17%-
Net Cash Per Share
7602.789912.9616277.2017754.3920850.38
Filing Date Shares Outstanding
78.2178.3576.8376.7876.5
Total Common Shares Outstanding
78.2178.3576.8376.7876.5
Working Capital
1,052,8521,266,0831,247,3501,403,6571,377,852
Book Value Per Share
23447.3123007.3722177.6022683.1220932.18
Tangible Book Value
1,706,4131,689,0451,689,6781,735,4031,597,339
Tangible Book Value Per Share
21819.3021558.4321993.0622601.0920880.24
Land
94,52171,30745,28045,2709,949
Buildings
432,036425,887124,315127,741119,990
Machinery
169,369174,92255,87953,14151,037
Construction In Progress
344,393231,27465,63833,15325,884
Source: S&P Global Market Intelligence. Standard template. Financial Sources.